Reports

Ideas That Generate Results

1. Analyst View

2. Research Methodology

3. Hepatocellular Carcinoma- An Introduction
    3.1 Etiology and Epidemiology of Hepatocellular Carcinoma
    3.2 Risk Factors

4. Market Dynamics
    4.1 Drivers
          4.1.1 Rising Incidences of Chronic Liver Diseases
          4.1.2 Increasing Aging Population
          4.1.3 Increasing R&D Investments
    4.2 Challenges
          4.2.1 Unsuccessful Clinical Trials
          4.2.2 Stringent Regulatory Challenges
    4.3 Opportunities
          4.3.1 Advancement of Cancer Drug Research
          4.3.2 Personalized Drug

5. Global Hepatocellular Carcinoma Drug Market Outlook 2022

6. Global Hepatocellular Carcinoma Drug Pipeline Analysis
    6.1 Hepatocellular Carcinoma Drug Pipeline by Industries
          6.1.1 By Clinical Phase
    6.2 Hepatocellular Carcinoma Drug Pipeline by Research and Collaborations
          6.2.1 By Clinical Phase

7. Market Segment by Geography
    7.1 North America
    7.2 Europe
    7.3 Asia Pacific

8. Company Profiles
    8.1 Pfizer Inc.
    8.2 Eli Lilly and Company
    8.3 Alnylam Pharmaceuticals, Inc.
    8.4 Exelixis, Inc.
    8.5 ArQule, Inc.
    8.6 Polaris Pharmaceuticals, Inc. (PPI)
    8.7 Bayer AG
    8.8 Teva Pharmaceutical Industries Ltd.
    8.9 Bristol-Mayers Squibb
    8.10 Celsion, Inc.